Credit Suisse Ag Praxis Precision Medicines, Inc. Transaction History

Credit Suisse Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$1.88 - $36.45 $29,100 - $564,209	-15,479 Reduced 99.99%	2 $0
Q3 2022 Nov 10, 2022	BUY	$2.5 - $37.95 $450 - $6,831	180 Added 1.18%	15,481 $35,000
Q2 2022 Aug 12, 2022	SELL	$1.75 - $11.34 $458 - $2,971	-262 Reduced 1.68%	15,301 $37,000
Q1 2022 May 16, 2022	SELL	$10.21 - $20.29 $9,842 - $19,559	-964 Reduced 5.83%	15,563 $159,000
Q4 2021 Feb 14, 2022	BUY	$16.76 - $22.99 $56,045 - $76,878	3,344 Added 25.37%	16,527 $327,000
Q3 2021 Nov 12, 2021	BUY	$13.15 - $22.56 $30,994 - $53,173	2,357 Added 21.77%	13,183 $243,000
Q2 2021 Aug 16, 2021	BUY	$18.28 - $33.05 $197,899 - $357,799	10,826 New	10,826 $197,000

75K

Ticker PRAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,576,100
Market Cap $3.26B
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.